Data do not support widespread Covid vaccine boosters right now, outgoing FDA leaders write in the Lancet
Even with the Delta variant, vaccine efficacy against severe Covid-19 is so high that booster doses for the general population are not appropriate at this stage in the pandemic, the FDA’s two top vaccine leaders, who recently announced their upcoming retirements on the same day, wrote in the Lancet on Monday.
The viewpoint, which was also co-authored by WHO and other academic experts from around the world, comes as the FDA is considering authorizing the use of boosters, with an adcomm of outside experts due to weigh in on Friday (briefing docs coming Wednesday).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.